- Home
- AIMD vs APLM Comparison
AIMD vs APLM Comparison
Compare AIMD & APLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIMD
- APLM
- Stock Information
- Founded
- AIMD 1984
- APLM 2016
- Country
- AIMD United States
- APLM United States
- Employees
- AIMD N/A
- APLM N/A
- Industry
- AIMD Biotechnology: Pharmaceutical Preparations
- APLM Blank Checks
- Sector
- AIMD Health Care
- APLM Finance
- Exchange
- AIMD Nasdaq
- APLM Nasdaq
- Market Cap
- AIMD 8.2M
- APLM 6.9M
- IPO Year
- AIMD N/A
- APLM N/A
- Fundamental
- Price
- AIMD $0.54
- APLM $4.63
- Analyst Decision
- AIMD
- APLM Strong Buy
- Analyst Count
- AIMD 0
- APLM 1
- Target Price
- AIMD N/A
- APLM $200.00
- AVG Volume (30 Days)
- AIMD 168.9K
- APLM 7.1K
- Earning Date
- AIMD 05-12-2025
- APLM 04-03-2025
- Dividend Yield
- AIMD N/A
- APLM N/A
- EPS Growth
- AIMD N/A
- APLM N/A
- EPS
- AIMD N/A
- APLM N/A
- Revenue
- AIMD $20,729.00
- APLM $198,000.00
- Revenue This Year
- AIMD N/A
- APLM $415.15
- Revenue Next Year
- AIMD N/A
- APLM N/A
- P/E Ratio
- AIMD N/A
- APLM N/A
- Revenue Growth
- AIMD N/A
- APLM N/A
- 52 Week Low
- AIMD $0.40
- APLM $4.71
- 52 Week High
- AIMD $1.46
- APLM $42.00
- Technical
- Relative Strength Index (RSI)
- AIMD 50.95
- APLM 29.97
- Support Level
- AIMD $0.51
- APLM $4.47
- Resistance Level
- AIMD $0.57
- APLM $5.45
- Average True Range (ATR)
- AIMD 0.04
- APLM 0.59
- MACD
- AIMD -0.00
- APLM -0.11
- Stochastic Oscillator
- AIMD 36.71
- APLM 5.18
About AIMD Ainos Inc.
Ainos Inc is engaged in developing biologics for the treatment of human and animal diseases. The company mainly focuses on the research of the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon-alpha that is administered in a proprietary low-dose oral form. Its product pipeline includes VELDONA Pet cytoprotein supplements for pets, VELDONA human therapeutics for clinical use, and telehealth-friendly POCTs powered by the AI Nose technology platform.
About APLM Apollomics Inc.
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.